Patent · US Expired

Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

US6562861B1 · kind B1 · utility

17Cited by

3References

41Claims

0Family size

Assignee

BioCryst Pharmaceuticals, Inc. · US

Inventors

Yarlagadda S. Babu · Birmingham, US
Pooran Chand · Birmingham, US
John A. Montgomery · Birmingham, US

Key dates

Filing date	May 25, 2000
Grant date	May 13, 2003
Priority date	—
Expiry date	May 25, 2020

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1′S)-(−)-(1′-acetylamino-2 ′-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.